Trexquant Investment LP Has $4.73 Million Stock Holdings in Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Trexquant Investment LP significantly increased its holdings in Supernus Pharmaceuticals, acquiring a total of 144,494 shares, which is valued at approximately $4.73 million.
• Corporate insiders have sold a total of 179,606 shares of Supernus Pharmaceuticals, amounting to $7.62 million in the last quarter, representing a notable decrease in their ownership.
• Recent analyst ratings for Supernus Pharmaceuticals have been positive, with upgrades from several firms, resulting in a consensus rating of "Moderate Buy" and a price target of $43.00.

Trexquant Investment LP boosted its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 94.5% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 144,494 shares of the specialty pharmaceutical company's stock after purchasing an additional 70,219 shares during the period. Trexquant Investment LP owned about 0.26% of Supernus Pharmaceuticals worth $4,732,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Vident Advisory LLC boosted its position in shares of Supernus Pharmaceuticals by 2.2% during the fourth quarter. Vident Advisory LLC now owns 14,392 shares of the specialty pharmaceutical company's stock worth $520,000 after buying an additional 309 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Supernus Pharmaceuticals by 2.4% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,664 shares of the specialty pharmaceutical company's stock worth $480,000 after buying an additional 350 shares during the period. Raiffeisen Bank International AG acquired a new position in shares of Supernus Pharmaceuticals during the fourth quarter worth approximately $25,000. PNC Financial Services Group Inc. boosted its position in shares of Supernus Pharmaceuticals by 4.7% during the first quarter. PNC Financial Services Group Inc. now owns 16,097 shares of the specialty pharmaceutical company's stock worth $527,000 after buying an additional 726 shares during the period. Finally, Quantinno Capital Management LP boosted its position in shares of Supernus Pharmaceuticals by 11.5% during the fourth quarter. Quantinno Capital Management LP now owns 8,401 shares of the specialty pharmaceutical company's stock worth $304,000 after buying an additional 864 shares during the period.

Insider Activity at Supernus Pharmaceuticals

In other news, CEO Jack A. Khattar sold 1,000 shares of the stock in a transaction on Monday, August 25th. The stock was sold at an average price of $45.00, for a total transaction of $45,000.00. Following the completion of the sale, the chief executive officer owned 1,071,459 shares in the company, valued at approximately $48,215,655. This represents a 0.09% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Frederick M. Hudson sold 7,457 shares of the stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $42.26, for a total value of $315,132.82. Following the sale, the director owned 46,307 shares of the company's stock, valued at $1,956,933.82. This trade represents a 13.87% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 179,606 shares of company stock worth $7,617,005. 8.80% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have recently issued reports on SUPN shares. Zacks Research upgraded Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Tuesday, August 19th. Cantor Fitzgerald boosted their price objective on Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 6th. Piper Sandler upped their target price on Supernus Pharmaceuticals from $36.00 to $40.00 and gave the stock a "neutral" rating in a research report on Friday, August 29th. Finally, Wall Street Zen upgraded Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Two investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $43.00.

Supernus Pharmaceuticals Stock Performance

Shares of SUPN stock traded up $0.59 during mid-day trading on Friday, hitting $46.02. 349,210 shares of the stock traded hands, compared to its average volume of 638,057. Supernus Pharmaceuticals, Inc. has a twelve month low of $29.16 and a twelve month high of $46.09. The firm has a market cap of $2.58 billion, a price-to-earnings ratio of 40.00 and a beta of 0.79. The company's 50-day simple moving average is $37.71 and its 200-day simple moving average is $34.10.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.